by Elena Iemma | Jun 23, 2026 | News
EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded...
by Elena Iemma | Jun 18, 2026 | Blog
Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic Global Regulatory Agency Perspective on NAMs as a Human-Relevant, Risk-Based Framework for Immunogenicity Recent FDA guidance and parallel global regulatory...
by Elena Iemma | Apr 2, 2026 | News
EpiVax Enters its Next Chapter with SV Health Investors EpiVax today announced its acquisition by SV Health Investors (SVHI), a healthcare and life sciences-focused private investment firm. This milestone marks an exciting new chapter and will accelerate further...
by Elena Iemma | Mar 18, 2026 | Blog
Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy Overview: A Strong Immunogenicity Risk Assessment Strategy Starts Early and Carries through Development Unexpected immunogenicity can derail even the most...
by Elena Iemma | Mar 18, 2026 | Uncategorized
Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy Overview: A Strong Immunogenicity Risk Assessment Strategy Starts Early and Carries through Development Unexpected immunogenicity can derail even the most...
